Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 4 Jan 2018

German Biotech Raises Record $270M Series A for Individualized Cancer Therapies

BioNTech will dedicate its huge fundraising to develop personalized cancer immunotherapies using CAR-T, TCR and mRNA technologies. BioNTech is kicking off the new year with great news. The company has closed its Series A with $270M (€225M) — a record amount in Germany for such an early funding round. The fundraising was led by the […]

January 4, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Dec 2017

Biota Beats: Music from the Microbiome

Bacteria and music are two completely unrelated concepts for most of us. But not for the group of artists and scientists behind Biota Beats. The iGEM synthetic biology competition gathers teams of enthusiastic students every year in Boston. But this year, it also gathered the bacteria of the participants. The team from Biota Beats asked […]

December 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Dec 2017

Scientists Find New Immune Target to Stop Progression of Alzheimer’s

Scientists have described a new mechanism by which the immune system can drive Alzheimer’s and shown that blocking it can prevent the disease in mice. A study published yesterday in Nature details how a molecule involved in the innate immune response can promote the aggregation of amyloid-β plaques that appear in the brains of patients […]

December 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Dec 2017

Israeli Biotech Acquires Microbiome Company to Fight Chronic Liver Disease

BiomX has acquired RondinX, expanding its bacterial target discovery platform and adding new microbiome targets for chronic liver disease. BiomX is a company based in Ness Ziona, Israel, developing customized phage therapy to selectively destroy the bacteria that cause diseases ranging from inflammatory bowel disease (IBD) to cancer. The company has just acquired RondinX, another […]

December 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Dec 2017

British Gene Therapy Gets a Huge £85M Boost in Series B

Orchard Therapeutics has raised a big round of financing to gene therapy options for many rare diseases for which there are no treatments. London-based Orchard Therapeutics has managed to raise £85M (€96M) in Series B, an amount that will certainly give an important boost to its pipeline of gene therapy treatments for rare diseases. The […]

December 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Dec 2017

This Gene Therapy for Hemophilia Can Reduce Bleeding by 70%

UniQure has published clinical data revealing that its gene therapy for hemophilia B is effective for years and lets patients stop weekly replacement therapy. From its headquarters in Amsterdam, uniQure is developing what could be one of the first gene therapies for hemophilia. A publication in the journal Blood yesterday details the results of a […]

December 19, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

granulomatous disease orchard therapeutics

News and Trends 18 Dec 2017

British Biotech Takes Over Development of Gene Therapy for Rare Immune Disease

Orchard Therapeutics has licensed a gene therapy for the rare genetic disorder X-linked chronic granulomatous disease (X-CGD) from the non-profit Généthon. London-based Orchard Therapeutics is adding a new program to its pipeline of gene therapies. The company has obtained an exclusive license to a lentiviral vector to treat X-linked chronic granulomatous disease and the clinical trial data […]

December 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

hpv cancer isa pharmaceuticals regeneron

News and Trends 18 Dec 2017

Dutch and US Biotechs Team Up Against HPV-related Cancer

ISA Pharmaceuticals will work together with Regeneron to combine its immunotherapy against cancer induced by HPV infection with its partner’s PD-1 checkpoint inhibitor. The human papillomavirus (HPV) is known for its ability to cause cancer, including cervical and head and neck cancer. Based in Leiden, the Netherlands, ISA Pharmaceuticals’ target choice is type 16 HPV, which […]

December 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 18 Dec 2017

French Biotech will work with the World’s Leader in Hearing Implants

Sensorion and Cochlear will explore if a combination of a drug and a hearing implant can improve the treatment of hearing loss. Based in the French city of Montpellier, Sensorion specializes in the development of treatments for inner ear disorders such as vertigo and hearing loss. The company’s technology received major recognition today with the […]

December 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Dec 2017

Science and Art Join Forces to Challenge our Anthropocentric Worldviews

Western culture seems to revolve exclusively around humans. It seems that we have forgotten the existence and the needs of all other organisms, from microscopic bacteria and fungi that make our food and medicines to the chickens and cows that feed us. But is this anthropocentric behavior justified? What are the consequences of our destructive attitude […]

December 16, 2017 - 6 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Dec 2017

The FDA Fast Tracks Therapy for Rare Disease Causing Copper Accumulation

The FDA is speeding up the process for regulatory approval of WTX101, a therapy for Wilson’s disease that could significantly improve the standard of care. Wilson Therapeutics, in Stockholm, has convinced the FDA to include its drug WTX101 (bis-choline tetrathiomolybdate) in its Fast Track program. This move will speed up the approval of the drug, […]

December 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 14 Dec 2017

New Biotech in Oxford Takes on Arthritis of the Spine

Izana Bioscience has been launched today to develop an antibody to treat ankylosing spondylitis, a form of arthritis that affects the spine. Oxford’s newest biotech, Izana Bioscience, has an exclusive license from Takeda to develop the antibody drug Namilumab (IZN-101) and a £1.35M grant from Innovate UK to fund a Phase II study. The company plans to […]

December 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us